Skip to main content
. Author manuscript; available in PMC: 2018 Sep 11.
Published in final edited form as: SLAS Discov. 2018 Mar 13;23(8):823–831. doi: 10.1177/2472555218763310

Figure 1.

Figure 1

Cell-based NBD1-targeted screen. (A) Schematic showing chimera construct consisting of the NBD1 domain of human CFTR linked to a single MSD of CD4 containing extracellular HA and HRP tags. (B) Immunoblot of MDCK cells expressing inducible HRP-CD4TM-WT-NBD1-1S (HRP-wild-type-NBD1) or HRP-CD4TM-ΔF508-NBD1-1S (HRP-ΔF508-NBD1) under the control of the TetON doxycycline (Dox)-regulated transactivator in the absence or presence of 500 ng/mL doxycycline for 2 days. Tubulin was the loading control. (C) Luminescence readout of cell surface HRP activity of MDCK cells expressing HRP-ΔF508-NBD1 after 24 h incubation with 500 ng/mL Dox at 37 °C with indicated compounds (SEM, n = 4) or at 27 °C. Data for MDCK cells expressing HRP-wild-type-NBD1 were shown as the positive control. Details of compounds in C are described in the text.